

W INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY of WASHINGTON

IBC Meeting Agenda

Date: Wednesday, April 16, 2025 **Time:** 10:00 a.m. – 12:00 p.m.

Location: Gateway Building (GWY), Room 649 (enter via main lobby and call 206-543-7262)
or access by remote dial in: +12063379723 US, Meeting ID: 928 0027 2001

1. **CALL TO ORDER**
 - Declaration of Quorum
2. **REMINDERS**
 - Public Disclosure & Conflict of Interest Policies
3. **APPROVAL OF MINUTES**
 - March 19, 2025
4. **OLD BUSINESS**
5. **BIOSAFETY OFFICER REPORT**
6. **BSL-3 INACTIVATION REPORT**
7. **DURC REPORT**
8. **DURC-PEPP DOCUMENTS FOR IRE**
9. **UPDATED BUA APPLICATION DOCUMENTS**

10. INDIVIDUAL PROJECT REVIEWS

Principal Investigator	Title	Project Type
Adams Waldorf, Kristina	<i>Nonhuman primate model of congenital toxoplasmosis</i>	new
Carr, Rotonya M	<i>The Pathogenesis of Insulin Resistance in Alcohol-associated and Metabolic Dysfunction-associated Steatotic Liver Disease</i>	renewal
Chavkin, Charles	<i>Chavkin-Mice</i>	renewal
Fuller, Deborah Lynn	<i>Nucleic Acid Mediated Protein Expression</i>	renewal
Giachelli, Cecilia M	<i>Vascular Calcification</i>	renewal
Jain, Aakanksha	<i>Neuronal regulation of tissue immunity</i>	new
Kennedy, Scott	<i>Somatic mutagenesis in aging and diseases</i>	change
Kiem, Hans-Peter	<i>In Vivo Gene Therapy</i>	new
Kwon, Young	<i>Regulation of growth and wasting</i>	renewal
Moreno, Claudia	<i>Mechanisms of Aging</i>	renewal
Murphy, Sean C	<i>Immunity to malaria infection</i>	renewal
Odom, Guy	<i>Cardiopulmonary gene therapy for muscular dystrophy</i>	renewal
Rajakovich, Lauren J	<i>Discovery and characterization of enzymes and metabolism in microbiomes</i>	renewal
Zheng, Ning	<i>Protein Structural Biology - Dr. Ning Zheng Lab</i>	renewal

11. SUBCOMMITTEE REPORTS

Principal Investigator	Title	Project Type
Nakamura, Kenta	<i>Endocardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment: A 26-Week (with 26 Week Extension) Phase 2b Randomized, Multi-Center, Double-Blind, Sham Controlled Study to Evaluate Efficacy and Safety</i>	new

W INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY of WASHINGTON

Portuguese, Andrew	<i>A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma</i>	new
Specht, Jennifer	<i>A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression.</i>	new
Specht, Jennifer	<i>A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Combination of CLBR001, an Engineered Autologous T Cell Product, and ABBV-461, an Antibody-Based Biologic, in Subjects with Locally Advanced or Metastatic Breast Cancer</i>	new
West, T. Eoin	<i>Host genetics and response to infection</i>	renewal
-	<i>Prion-like proteins (PLPs)/Proteopathic Seeds Subcommittee</i>	new

12. FOR YOUR INFORMATION

13. ISSUES FROM THE FLOOR & PUBLIC COMMENTS

14. ADJOURNMENT